# Pizarra — PT-pseudo_4e545d350c5b (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_4e545d350c5b
Task: 1

Encounter: Urology - outpatient on 09 Feb 2025.
Referrer: Dr. N. Kuiper (GP).
Type: Follow-up - PSA + MRI.

Clinical data (read-only — values loaded from the record):
  - 68-year-old male
  - PSA: 22.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.696 ng/mL²
  - PSA velocity: 2.9 ng/mL/yr
  - Prior PSA: 19.9 ng/mL
  - Prostate volume: 31.63 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: None (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.8591883 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: Penicillin (rash)
  - Additional notes: PSA 22 ng/mL. PI-RADS 5. PSAD 0.70. Prostate volume 32 mL. csPCa 0.86.

Vitals: weight 85 kg, height 181 cm, BMI 25.9, BP 120/77 mmHg, HR 64 bpm. Smoking: Ex-smoker (20 pack-yr, quit 2013).

Chief complaint: Persistent prostate-specific antigen elevation alongside recent imaging findings prompted this consultation.

History: Serial prostate-specific antigen measurements demonstrating a steady climb initiated a prolonged urological evaluation for this 68-year-old man. He works as a retired firefighter and resides with his partner, maintaining a brisk pace through weekend hikes. Lower urinary tract complaints surface moderately, yielding an IPSS of 10 driven mainly by occasional hesitancy and mild nocturia. He firmly denies unexplained weight loss, pelvic discomfort, or blood in the urine. Medical background remains clear apart from a distant appendectomy during his twenties and a recent dermatology appointment for actinic keratosis treatment. Former smoking habits total 20 pack-years, though he ceased tobacco use in 2013. Alcohol intake averages nine units each week. Mild visual impairment dictates large-print correspondence, and his adult daughter acts as his main liaison. An autumn 2024 cardiology assessment confirmed steady cardiovascular health without any current prescriptions. Comorbid conditions are absent. Marital status is divorced.

Physical examination: DRE: texture smooth and uniform; mobility intact; no focal nodules or dimensional irregularities detected. The gland measures within normal parameters and presents bilaterally symmetric. General assessment shows stable vital markers and absence of lymphadenopathy or systemic disease indicators. Nutritional status appears robust, and functional mobility remains excellent.

Patient info: retired firefighter; Divorced; Lives with partner.
Next of kin: Adult daughter (primary contact).

Lifestyle: alcohol 9 units / week; exercise Hiking on weekends; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Cardiology — annual review (stable, autumn 2024); Dermatology — actinic keratosis check.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.78 +/- 0.10   (95% CI 0.58-0.97)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.10  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.77 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'firm': p +/- 1.96*dp does not cross the 0.5 threshold. Treat it as a strong prior that should only be overturned by explicit contradicting evidence. Measured accuracy in this tier on the labelled cohort: 1.0 over 28 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: biopsy-naive.

CRITERION VERDICT: BIOPSY.

The criterion: Biopsy when the mpMRI shows a PI-RADS 3 or higher lesion; defer when PI-RADS is 1-2.

In the labelled cohort this criterion matched the reading urologist in every one of the 24 biopsy-naive cases (20 of them PI-RADS 4-5 and biopsied, 4 of them PI-RADS 2 or unreadable and deferred).

Track record of this criterion on the labelled cohort: 24 of 24 cases matched the reading urologist. Departing from it needs a specific finding from a retrieved document, named explicitly - not a restatement of the panel numbers it already used.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the mpMRI show a PI-RADS 3 or higher lesion?
  - psa_trend (get_psa_trend) -> Is the PSA trend significant enough to warrant immediate action?
  - previous_notes (get_previous_notes) -> What is the prior management context and agreed-upon surveillance pathway?

This case hinges on the interpretation of the PI-RADS 5 finding and the need to confirm the clinical context (history and trend) before proceeding with the biopsy recommendation.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel and parsed record. It could not weigh the specific PSA velocity (2.9 ng/mL/yr), the high csPCa probability (0.8591883), or the specific PI-RADS 5 score against the DRE finding of "Normal."

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy (p=0.78) based on the structured panel, but the guideline criterion is PI-RADS $\ge 3$. The prior did not explicitly weigh the high csPCa probability (0.86) against the DRE being normal, which could suggest a benign finding despite the high imaging score. The high aleatoric uncertainty (H=0.77) suggests the model struggles with this specific clinical conflict.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the mpMRI show a PI-RADS 3 or higher lesion?
psa_trend - Is the PSA trend significant enough to warrant immediate action?
previous_notes - What is the prior management context and agreed-upon surveillance pathway?
laboratory panel - What are the full laboratory results?

GUIDELINE ANCHOR
The guideline states that a PI-RADS $\ge 3$ triggers biopsy, and the track record shows that this criterion matched the reading urologist in 24 out of 24 biopsy-naive cases.

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_4e545d350c5b", "radiology_report": "PI-RADS 5 lesion in the right posterior peripheral zone. csPCa predicted probability 0.8591883."}
get_psa_trend
{"case_id": "PT-pseudo_4e545d350c5b", "psa_trend": [{"date": "Feb 2023", "val": 11.9}, {"date": "Oct 2023", "val": 15.7}, {"date": "Jun 2024", "val": 11.7}, {"date": "Feb 2025", "val": 22.0}]}
get_previous_notes
{"case_id": "PT-pseudo_4e545d350c5b", "previous_notes": [{"date": "14 Jun 2024", "author": "Dr. N. Kuiper (GP)", "text": "A PSA reading of 19.9 ng/mL prompted a routine clinical review. We examined the consistent upward trend observed since the first elevation in February 2023 and emphasized the necessity for specialist urological evaluation. Arrangements for a multiparametric MRI and dedicated assessment are now in place."}, {"date": "15 Feb 2024", "author": "Dr. N. Kuiper (GP)", "text": "Clinical follow-up centered on a PSA measurement of 17.8 ng/mL. Physicians reviewed the progressive climb documented since early 2023, and the patient received counseling on potential clinical implications. Voiding function remains entirely symptom-free."}]}

NOT RETRIEVED
laboratory panel
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no specific question arose from the retrieved documents that necessitated its opening.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right posterior peripheral zone.
- PSA trend: PSA velocity is 2.9 ng/mL/yr, with a recent jump to 22.0 ng/mL.
- Previous notes: Prior evaluation prompted MRI and assessment due to a consistent upward trend in PSA.

AGAINST sampling this patient now:
- DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).

WHERE THIS LEANS
The evidence strongly supports biopsy due to the high-risk PI-RADS 5 finding and the significant PSA velocity, aligning with the guideline criterion.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=yes, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (PI-RADS 5 on MRI, significant PSA trend, and prior evaluation context) strongly supports the guideline criterion for biopsy. The record is sufficient to proceed to the final decision.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision to biopsy is supported by convergence across all sources. The guideline criterion mandates biopsy for a PI-RADS 5 lesion, which was retrieved from the MRI report. This finding, combined with the significant PSA velocity of 2.9 ng/mL/yr, strongly supports the recommendation. The statistical prior also suggested biopsy, and the retrieved evidence confirmed the clinical context supporting this action.

Variables that carried weight: age=important, psa=important, vol=noted, psad=important, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
